All News | RheumNow

All News

Hold the Methotrexate for One Week

Save

d Jack Cush, MD

Jul 18, 2023

In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.

Read Article

pregn.outcome.jpg

SLE and Pregnancy Outcomes

Save

d Jack Cush, MD

Jul 17, 2023

Obstetric complications and poor pregnancy outcomes are not uncommon in women with SLE, especially with active disease. A large Spanish cohort trials shows that term pregnancy is more likely before the diagnosis of SLE and that poorer pregnancy outcomes were associated with antibody positivity to anticardiolipin IgG and anti-beta-2- glycoprotein IgG/IgM, but not lupus anticoagulant.

Read Article

PSA%20026.jpg

EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis

Save

d Jack Cush, MD

Jul 17, 2023

The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.

Read Article

Research from 12 states with medical cannabis laws looked at 583 820 adults w/ chronic noncancer pain. Data over 3 yres shows < 0.05% change in the use of opioid prescriptions, nonopioid prescriptions, pain meds, or chr pain procedures https://t.co/ArbP4xe4dH https://t.co/MPRBZNIIoS

Links:

https://bit.ly/3Dg0OKa

Dr. John Cush RheumNow ( View Tweet)

Jul 18, 2023

Top 10-selling drugs accts for 22% of Medicare part D spending ($47.7/$215.7 billion) Eliquis $12.6 Billion Trulicity $4.7 B Januvia $4.1B Jardiance $3.7B Lantus $2.8B Ozempic $2.6B Revlimid $5.9B Xarelto $5.2B Imbruvica $3.2B Humira $2.9B https://t.co/5rvLldNLF0 https://t.co/OOt8he8Ig4

Links:

https://bit.ly/44vyu2m

Dr. John Cush RheumNow ( View Tweet)

Jul 18, 2023

In AUSTRALIA, 30% (~ 7million) have a chronic #MSK condition, costing $14.6 billion (10% of all healthcare spending) in 2019-20. Overall, 4 million w/ back problems, 3 million arthritis, 900,000 osteoporosis, 450,000 w/ #RA. https://t.co/TDV50PoRXj https://t.co/EtSUuv6jMA

Links:

https://bit.ly/3K1GwIc

Dr. John Cush RheumNow ( View Tweet)

Jul 18, 2023

Filgotinib Effects on Semen and Sex Hormones The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. https://t.co/SrwInSY45G https://t.co/TD54PXNFbi

Links:

https://bit.ly/3rqYnSq

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2023

Antidrug Antibodies Impair Response to Biologic Drugs Monitoring for antidrug antibodies with biologic has not been routine in rheumatology but a new study suggests that antidrug antibodies correlate with nonresponse to bDMARDs in RA patients. https://t.co/tMxZpbyJl1 https://t.co/VCUdkp8I15

Links:

https://bit.ly/3rzHchp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2023

Remembering Dr. Naomi F. Rothfield - As one of UConn School of Medicine’s first women faculty, legendary internationally-renowned rheumatologist Dr. had a nearly 50 year career at UConn Health retiring in 2016. She passed away on Sunday, July 2. https://t.co/D3vJzXQCnz https://t.co/YajGbGWpKf

Links:

https://bit.ly/44tlcng

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2023

Scary Outcomes with Systemic Sclerosis Sine Scleroderma The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc. https://t.co/DMZTLKwmHv https://t.co/2bXqMt7H1z

Links:

https://bit.ly/3NRjNQ8

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2023

Review of DMARDs on the immunogenicity of vaccines by Winthrop: - reduced by B cell depletion, MMF, CTX, AZA, ABA - no effect: IL-6 inhibitors & HCQ - MTX & steroids: gen suppressed by depends on dose & vaccine type https://t.co/mh8xDnwpim https://t.co/44HJjPq0BS

Links:

https://go.nature.com/3NR5yLj

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2023

Multicenter open label trial of 30 refract. Behcets (BD) pts treated w/ tocilizumab (TCZ) x 6 mos; TCZ was effective in 83% (18 complete & 7 partial resp). Complete responses seen w/ uveitis 67%, CNS 60%, mucosal 42%, articular 21%; plus steroid sparing https://t.co/PfrAoQxC2F https://t.co/ocAFv0Y2kr

Links:

https://bit.ly/44KT1zU

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2023

Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/uRLJdO8A2j https://t.co/brNX6ZSfqq

Links:

https://bit.ly/3Dctzrl

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2023

Pre-Clinical RA - Clinical Trial Outcomes https://t.co/EIG1eam31h https://t.co/6rYcGmgJG5

Links:

https://bit.ly/46Q48ZX

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2023

JAMA: Prophylaxis for Pneumocystis Pneumonia - indications and Rx - Immuncompromised and Immunodeficient - Pts on Hi Dose Steroids - ANCA–associated vasculitis https://t.co/GjtkgeZE8b https://t.co/1I1jjrI5s8

Links:

https://bit.ly/46Jrqkt

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2023

988 -- the new 3 digit Suicide and Crisis Lifeline (available since July 2022). You don't need to be in crisis or suicidal to call 988 and speak with a counselor. It is a free service available at all hours, day or night, for anyone who needs support. https://t.co/RfTfmHbvxJ https://t.co/JPihu6XOyu

Links:

https://nyti.ms/3XRrWbO

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2023

A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/ZvsfB0Pjqh https://t.co/oFmbQXVbct

Links:

https://bit.ly/3Dbkgb4

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2023

Full read review of "Treatments for Lupus Nephritis" from Isenberg et al - discussing: - Pathogenesis, outcomes - Conventional Rx - B cell targeting: BEL, RTX, Obintuzumab, Atacicept & more - Sequential Rx: Synviose, BEAT, BLISS-Believe - JAKi & more https://t.co/TiHyK4ffms https://t.co/dmFXbMxKsE

Links:

https://bit.ly/3pIeM4y

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2023

Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC

Links:

https://bit.ly/3XYQPCI

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2023

Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/4c4oQwY9G6 https://t.co/iRa7wG5yOv

Links:

https://bit.ly/3NWl34u

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2023

×